
    
      This is a randomised, single-center, open-label, single-dose, two-period crossover
      pharmacokinetics study of donepezil HCl tablets 3 mg in subjects receiving haemodialysis.
      Subjects will be or will not be receiving haemodialysis. After intervals of over 15 days, the
      subjects will be receiving the other treatment.
    
  